Edition:
United States

Meridian Bioscience Inc (VIVO.OQ)

VIVO.OQ on NASDAQ Stock Exchange Global Select Market

14.25USD
15 Dec 2017
Change (% chg)

$0.70 (+5.17%)
Prev Close
$13.55
Open
$13.55
Day's High
$14.30
Day's Low
$13.55
Volume
426,177
Avg. Vol
67,043
52-wk High
$18.30
52-wk Low
$10.77

Select another date:

Tue, Dec 12 2017

BRIEF-Co-Diagnostics Announces Sale Of Molecular Diagnostic Tests

* CO-DIAGNOSTICS, INC. ANNOUNCES SALE OF MOLECULAR DIAGNOSTIC TESTS, INCLUDING ZIKA VIRUS, TO MAJOR CARIBBEAN LABORATORY Source text for Eikon: Further company coverage:

BRIEF-Meridian Bioscience Files For Mixed Shelf Of Up To $100 Million

* MERIDIAN BIOSCIENCE INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source text: (http://bit.ly/2k7rdVf) Further company coverage:

BRIEF-Co-Diagnostics Inc says qtrly loss per share $‍0.33​

* Co-Diagnostics, Inc. Reports Q3 financial results and updates corporate developments

FDA warns Meridian of violations for lead-testing devices

(This Oct. 23 story corrects paragraph 4 to say warning letter, instead of form 483)

CORRECTED-UPDATE 2-FDA warns Meridian of violations for lead-testing devices

Oct 23 The U.S. Food and Drug Administration said on Monday it issued a warning letter to Meridian Bioscience Inc's unit for several federal law violations after inspecting its facility that makes lead-testing devices.

BRIEF-Meridian Bioscience says FDA issued warning letter related to matters at Magellan Diagnostics subsidiary​

* Meridian Bioscience Inc - ‍announced that FDA has issued a warning letter related to matters at its Magellan Diagnostics subsidiary​

FDA warns Meridian of violations for lead-testing devices

Oct 23 The U.S. Food and Drug Administration said on Monday it issued a warning letter to Meridian Bioscience Inc's unit for several federal law violations after inspecting its facility that makes lead-testing devices.

BRIEF-Meridian bioscience comments on preliminary fiscal 2017 operating results

* Meridian Bioscience Inc comments on preliminary fiscal 2017 operating results and provides fiscal 2018 revenue and earnings guidance

BRIEF-MERIDIAN BIOSCIENCE APPOINTS JACK KENNY AS CEO

* MERIDIAN BIOSCIENCE, INC. APPOINTS JACK KENNY AS CHIEF EXECUTIVE OFFICER

BRIEF-Meridian Bioscience introduces expansion of its ImmunoCard STAT! product line

* Meridian Bioscience Inc- ‍Announced expansion of its ImmunoCard Stat! product line with addition of ImmunoCard Stat! FLU A&B​ Source text for Eikon: Further company coverage:

Select another date: